DRUG
Gonadotropin
Giving patients gonadotropins and antagonist cetrotide
Status
Unknown
Phase
Phase 4
Enrollment
200
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The new protocol ANTIUI provides good results regarding ovulation and pregnancy rates in patients with unexplained infertility
Full detailed description
Patients with unexplained infertility has normal investigations regarding hormonal, structural data. Semen is normal but no pregnancy occurs. Before trying ICSI, we could help these patients with ANTIUI
Interventions
Treatment arms and agents.
DRUG
Standard protocol in IUI
Giving patients gonadotropins without antagonist cetrotide
Timeline
From registration to results.
First posted
Feb 15, 2021
Study start
Mar 1, 2021
Primary completion
Dec 31, 2024
Study completion
Dec 31, 2024
Results posted
Not reported
Registry updated
Jul 18, 2023
Outcomes
What the study measures.
Primary outcomes
Ovulation
Time frame · 6 months
Disappearance of mature follicle
Pregnancy
Time frame · 6 months
Number of pregnant cases
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 20 Years
- Maximum age
- 35 Years
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * Unexplained infertility * Duration less than 5 years * Good ovarian reserve AMH\> 1.1 * Normal patent tubes * No previous trials of IUI with the same protocol Exclusion Criteria: * Age \> 35 years * Duration of infertility\> 5 years * Abnormal semen * Hypoplastic tubes * prior failed ICSI
Study locations
1 registered sites.
Egypt. Showing up to 24 locations stored in the fast local snapshot.
Ayman Shehata Dawood
Tanta, Gharbia Governorate, Egypt
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.